Genetic Markers of Therapeutic Efficacy of Methotrexate in Patients with Psoriasis

被引：3
作者：
Voron'ko, O. E. [1 ]
Baskaev, K. K. [1 ]
Sobolev, V. V. [2 ,3 ]
Denisova, E., V [2 ]
Korsunskaya, I. M. [2 ]
机构：
[1] VN Orekhovich Res Inst Biomed Chem, Moscow, Russia
[2] Russian Acad Sci, Ctr Theoret Problems Physicochem Pharmacol, Moscow, Russia
[3] II Mechnikov Res Inst Vaccines & Sera, Moscow, Russia
来源：
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2022年 / 172卷 / 04期
关键词：
psoriasis; methotrexate; genetic markers; thymidylate synthase; methylenetetrahydrofolate reductase (MTHFR); METHYLENETETRAHYDROFOLATE REDUCTASE GENE; RHEUMATOID-ARTHRITIS; POLYMORPHISMS; TOXICITY; ELEVATION; MTHFR; C677T;
D O I：
10.1007/s10517-022-05413-6
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We studied the effect of C677T and A1298C polymorphisms of the MTHFR gene and 2R/3R polymorphisms of the TYMS gene on the sensitivity to methotrexate in patients with psoriasis (n=139). It was shown that genotype 3R/3R TYMS (OR 8.86, 95%CI 2.00-39.22) and complex genotypes MTHFR1298:A;TYMS:3R (OR 8.20, 95%CI 2.36-28.48) and MTHFR677:C;TYMS:3R (OR 5.40, 95%CI 1.95-14.94) were associated with sensitivity to methotrexate, while genotype 2R/2R TYMS (OR 8.20, 95%CI 2.36-28.48) and complex genotypes MTHFR1298:C;MTHFR677:T;TYMS:2R (OR 0.18, 95%CI 0.06-0.56) and MTHFR1298:C;MTHFR677:T (OR 0.23, 95%CI 0.09-0.59) were associated with resistance to methotrexate. The results can be used for preventive assessment of the effectiveness of methotrexate treatment in patients with psoriasis.
引用
收藏
页码：460 / 463
页数：4
相关论文
共 16 条
  • [1] [Anonymous], 2016, Global report on psoriasis
  • [2] Arsenyev YeV, 2020, Effektiv. Farmakoter, V16, P50, DOI [10.33978/2307-3586-2020-16-6-50-57, DOI 10.33978/2307-3586-2020-16-6-50-57]
  • [3] Bae SC, 2018, Z RHEUMATOL, V77, P824, DOI 10.1007/s00393-018-0419-4
  • [4] Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis
    Choe, Jung-Yoon
    Lee, Hwajeong
    Jung, Hyun-Young
    Park, Sung-Hoon
    Bae, Sang-Cheol
    Kim, Seong-Kyu
    [J]. RHEUMATOLOGY INTERNATIONAL, 2012, 32 (06) : 1837 - 1842
  • [5] Pharmacogenetic Polymorphisms Contributing to Toxicity Induced by Methotrexate in the Southern Spanish Population with Rheumatoid Arthritis
    Cristian Plaza-Plaza, Jose
    Aguilera, Margarita
    Canadas-Garre, Marisa
    Chemello, Clarice
    Gonzalez-Utrilla, Alfonso
    Faus Dader, Maria Jose
    Angel Calleja, Miguel
    [J]. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2012, 16 (11) : 589 - 595
  • [6] [Девальд Инесса Валерьевна Devald Inessa], 2019, [Научно-практическая ревматология, Rheumatology Science and Practice, Nauchno-prakticheskaya revmatologiya], V57, P149, DOI 10.14412/1995-4484-2019-149-153
  • [7] Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism
    Grabar, Petra Bohanec
    Logar, Dusan
    Lestan, Boris
    Dolzan, Vita
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (11) : 1057 - 1068
  • [8] [Коротаева Татьяна Викторовна Korotaeva Tatiana Viktorovna], 2013, [Современная ревматология, Sovremennaya revmatologiya], V7, P45
  • [9] Kumagai K, 2003, INT J MOL MED, V11, P593
  • [10] Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases
    Mena, J. P.
    Salazar-Paramo, M.
    Gonzalez-Lopez, L.
    Gamez-Nava, J. I.
    Sandoval-Ramirez, L.
    Sanchez, J. D.
    Figuera, L. E.
    Munoz-Valle, F. J.
    Vazquez del Mercado, M.
    Davalos, I. P.
    [J]. PHARMACOGENOMICS JOURNAL, 2011, 11 (04) : 287 - 291
12